Plaintiffs take aim at Pfizer and GlaxoSmithKline in California federal court for “natural” ChapStick claims, while Sanofi US is defending the naturalness of Selsun Blue Naturals Antidandruff Shampoo in New York’s Eastern District.
Plaintiffs are taking on consumer health giants in California and New York federal courts in another go at “natural” claims.
Join thousands of industry professionals who rely on HBW Insight for daily insights
Already a subscriber?
The Washington State Department of Ecology will try to work with companies that violate the Toxic Free Cosmetics Act, rather than reflexively imposing the $5,000-per-violation fine for first-time offenders, says the law’s implementation planner. She noted financial assistance is available for small businesses, as well as incentives for companies adopting measures “beyond compliance.”
US FDA Office of New Drugs Director Peter Stein says review divisions have made the case that a discussion-only meeting would solicit the necessary input.
Requests for “enforcement actions are not within the scope of FDA’s citizen petition procedures,” CDER says, rejecting petition dosing device firm Parenteral Technologies submitted as it prepares for workshop on Pediatric Research Equity Act requirements for OTC NDA sponsors.
